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Yearly 1-2 in 1.000 individuals from the general population of Western countries 
will suffer a deep venous thrombosis (DVT). In the elderly the incidence can be as 
high as 1 in every 100 individuals. Up to half of DVT patients will develop the post-
thrombotic syndrome (PTS). With the aging of the population as a whole, both the 
medical and economic impact of DVT and PTS will gravely increase. However, in both 
the medical world and layman media PTS is an underappreciated subject. Before the 
advent of deep venous stenting there was no causative treatment modality. Relatively 
effective symptom reduction therapy was possible in many PTS patients, mostly by 
use of compression garments and sometimes analgesics. However, some still suffered 
incapacitating symptoms, e.g. gross lower limb swelling and debilitating pain during 
mobilization. Moreover, many PTS patients never received this minimal level of care, 
and thus were undertreated.  PTA and stenting in venous disease was introduced as a 
routine daily practice at the end of the 1990’s in a number of centres worldwide, most 
notably in the United States of America. Since then it has slowly gained attention 
and implementation in more and more specialized centres worldwide. However, 
widespread knowledge about this treatment is still lacking in general medical daily 
care. This thesis is characterized by a number of unique studies, i.e. the description of 
the first clinical results of a specially designed dedicated venous stent (the sinus Venous 
stent) in chapter 4 and the first study reporting a mid-sized population treated by the 
combination of PTA, stenting, endophlebectomy and AV-fistula creation, offered as a 
standardized intervention in chapter 7. Moreover, the study in chapter 8 describing the 
clinical outcome of the total population of treated patients is one of the largest series 
available in current literature. 
Therefore, this thesis adds a substantial body of data in favour of interventional treatment 
of PTS and IVCS. Many patients who are currently not treated for the underlying cause 
of their venous symptoms can benefit from PTA and stenting. As chronic treatment 
with medication and compression garments can be very expensive, especially in cases 
of venous ulceration, PTA and stenting might drastically reduce healthcare costs on the 
long term. 
 
Target population in and outside the medical field
Primarily the results of PTA and stenting in chronic venous obstructive disease are of 
special importance to (vascular) surgeons, (interventional) radiologists, dermatologists, 
phlebologists, internists, geriatrists and general practitioners. Moreover, anyone in the 
field of medical device development, be it researchers or medical device companies, can 
find new targets or support for their products. A whole new field within the specialties 
of surgery and radiology are explored in this thesis. Also, government bodies and health 
insurance companies might be interested in the role of PTA and stenting in combating 
ever increasing healthcare costs, as this treatment may prevent the high costs from 
decades of conservative treatment.  
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Activities and implementations resulting from this thesis
The sole treatment by use of PTA and stenting has gained some attention during the 
last few years. However the routine use of endophlebectomy and AV-fistulas in the most 
severe cases of PTS is a relative novelty. Other centres worldwide might be moved to start 
using this treatment themselves, or find alternative ways to treat these gravely affected 
patients. Moreover, the use of dedicated venous stents can be implemented in many 
already ongoing or in new venous obstruction treatment protocols. Furthermore, these 
encouraging results with the first generation of dedicated venous stents can motivate 
medical corporations to invest in better tools, stents and other devices. However, the 
most important activity for the near future will be to bring the knowledge and the 
clinical potential of this treatment modality in the attention of the medical world as a 
whole. 
Innovation  
The most important innovation resulting from this thesis should be the improvement 
of care of patients suffering from deep venous pathology. Every patient suffering 
from PTS should have the opportunity to be evaluated by a physician knowledgeable 
about this subject, and if eligible be treated accordingly. Furthermore, the severity of 
the disease described in this thesis might add to the discussion of how DVT should 
be managed. As already stated many patients treated by conservative therapy for DVT 
(anticoagulation and compression) will develop PTS. The best management of PTS 
includes the prevention of PTS at the time of the initial DVT. Currently a number of 
thrombus removal techniques are under research, and some are already implement in 
specialized centres worldwide. PTA and stenting as a primary treatment might have 
a role in DVT prevention in IVCS patients.  In their classical 1957 paper the authors 
May and Thurner recognized the role of the common iliac vein compression in left 
sided DVT pathogenesis, and indeed this was already hypothesized by Rudolf Virchow 
a century earlier. Treating this iliac compression, in patients who already suffer from 
chronic venous obstructive symptomatology, may have a profound effect in preventing 
DVT, and subsequent PTS development. The same can be said about the prevention 
of secondary DVT in PTS patient, however in these cases the thrombogenic effect of 
stenting itself needs to be taken into consideration.  
Realisation of future activities and research
Convincing the medical world as a whole to take treatment of venous disease to the 
next level will be the most important aim of future research. To achieve this randomized 
controlled trials and great registries are needed. Development of a RCT protocol is 
currently taking place in our own centre.  The American Venous Forum has already 
started a registry aimed at venous stenting in the United States of America.  An European 
counterpart should be appropriate. 
In order to improve the current treatment strategies, a number of subjects need to 
be studied more in-depth. Firstly, the protocol of post-interventional anticoagulation 
should be investigated. Currently, anticoagulation is not able to prevent a significant 
number of rethrombosis. Moreover, treatment might be too aggressive in a great number 
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of patients, especially those without a prior thrombotic event; the IVCS patients. 
Secondly, even though the introduction of dedicated venous stent designs has helped 
in attacking a number of specific stent related complications, these complications 
are still present after a significant number of interventions. Further improvement of 
stent design might be helpful in this respect. Thirdly, the use of endophlebectomy and 
temporary AV-fistula creation has helped us in providing a causative treatment for even 
those PTS patients most severely affected by post-thrombotic vein damage. However, 
these operations are characterized by specific complications, especially the occurrence 
of stenoses at the level of the treated vein and the frequently problematic wound healing. 
Ideally these complications can be avoided. Options might be the preventive use of VAC 
therapy aimed at the wound healing disorders, and the use of special intra-operatively 
deployable inlays for the endophlebecomized common femoral vein.  
In conclusion it can be stated that the world of deep venous reconstructions is still in its 
infancy. Much efforts will be needed to reach the next stage, but this has the potential to 
revolutionize the field of vein disease. 
    
   
